Glaucoma
Conditions
Keywords
glaucoma, compliance, eye drops, deliver aid, Patients could range anywhere from 40 to 80 years old, Patients must have diagnosis requiring treatment with Xalatan., Patients will be male or female and from any racial/ethnic background.
Brief summary
The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN
Interventions
DEVICEXal-Ease device to be used with Xalatan eye drops
This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
Sponsors
Pfizer
Augusta University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 40 to 80 years old * Diagnosis warranting treatment with Xalatan eye drops. * ambulatory and well functioning
Exclusion criteria
* non-ambulatory * less than 40 or greater than 80 years old * Not using Xalatan eye drops
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment. | six months |
Secondary
| Measure | Time frame |
|---|---|
| To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen | six months |
| To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye. | 6 months |
Countries
United States
Contacts
Primary ContactChristian D. Nilson, MD
Backup ContactSandra M. Johnson, MD
Outcome results
None listed